To determine the mitND6 gene mutations in lung adenocarcinoma specimens, we compared each of the mitND6 gene sequences of 87 patients to the Cambridge Reference Sequence.
For the analysis of the in vitro potency of various treatments against LIC in xenograft specimens, we compared the mean spleen size and spleen cellularity of mice inoculated with xenograft cells that were subjected to the respective treatments prior to injection.
Because of the unreliability of the mean reported by Berger et al. [1] for femoral head diameter (see note below Table 1) and that Nelson and Fitzpatrick [3] report only the maximum head diameter for specimen -003, we compare the mean for maximum femoral head diameter from Orrak to that from Omedokel.
The sex of the individuals represented by these specimens is unknown, and therefore we compare these mass estimates to the mean mass estimate derived from a pooled sex sample of Onge femora (12 females, 12 males and 14 specimens of indeterminate sex).
By applying our procedure for stratification and normalization to tumor specimens on different aCGH platforms we compare performance with standard methods.
To examine potential contamination of specimens, we also compared the distributions of free phenol and paraben concentrations as a percentage of the total concentration for the five compounds with sufficient detection: BPA, butyl paraben, methyl paraben, propyl paraben, and benzophenone-3.
In our study, we compared specimen results in terms of sensitivity and specificity that were taken with bronchoalveolar lavage (BAL) fluid and endotracheal aspirates (ETA) and we examined the value of clinical pulmonary infection score (CPIS) in the diagnosis of VAP.
We compared specimens occurring within Guanabara Bay (site P92) with those of the Cagarras Archipelago (CA).
Using pretreatment biopsy specimens in these patients, we compared the effectiveness of NACRT with the expression of Rad51.
However, this difference disappeared when we compared case specimens collected 1 to 39 days prior to surgery to the healthy controls (figure 2c, solid line).
